Description
What is the Sermorelin + Ipamorelin (5/5) Blend?
This co‑lyophilized research blend pairs Sermorelin (5 mg, GHRH 1–29 amide) with Ipamorelin (5 mg, selective pentapeptide ghrelin‑receptor agonist) in a single vial. The short half‑life of both constituents favors pulsatile‑pattern preclinical research—as opposed to the sustained kinetics of CJC‑1295‑DAC‑based pairings.
Mechanism of Action — Combined
- Sermorelin: GHRHR agonist via GHRH(1–29); short half‑life (~10–20 min); preserves pulsatile GH release and HPA feedback
- Ipamorelin: Selective GHS‑R1a agonist; no significant cortisol/prolactin elevation
- Synergy: Paired GHRH + GHS activation produces supra‑additive GH pulses in preclinical models
Compound Properties
- Composition: Sermorelin 5 mg + Ipamorelin 5 mg per vial
- Form: Lyophilized powder (co‑lyophilized blend)
- Source: Each peptide individually ≥98% by HPLC prior to blending
Research‑Reference Dosing
Published research‑reference ranges (for each constituent):
- Thorner et al., JCEM (1988); Prakash & Goa, BioDrugs (1999): Sermorelin (GHRH 1–29) pharmacology.
- Raun et al., European Journal of Endocrinology (1998): Ipamorelin characterization.
- Bowers et al.: GHRH + GHS synergy literature.
- No peer‑reviewed clinical trials of this specific 5/5 blend formulation.
Research Findings
- Paired pulsatile GH release with preserved HPA/GH‑axis feedback architecture
- Both constituents are relatively clean on the cortisol/prolactin axis
- Common preclinical protocol for “bioidentical‑pattern” GH research
Known Side Effects Reported in Research/Trials
- Injection‑site erythema or pain
- Flushing, transient headache, dysgeusia (GHRH class)
- Sustained dosing may elevate IGF‑1 with associated class effects (water retention, arthralgia)
- Long‑term human safety data for combined formulation is unavailable
Storage & Handling
- Lyophilized (unreconstituted) vials: store at −20°C long‑term; short‑term 2–8°C acceptable.
- After reconstitution with bacteriostatic or sterile water: store at 2–8°C; use within 14–28 days per standard peptide stability guidance.
- Protect from light, heat, and repeated freeze‑thaw cycles. Handle in a sterile laboratory environment.
Certificate of Analysis
A Certificate of Analysis (COA) confirming identity and purity by HPLC / MS is available upon request. Contact Lonestar Peptides for lot‑specific documentation.
Summaries reference peer‑reviewed preclinical and clinical literature available as of early 2025. Newer findings may not be reflected. Researchers should consult current literature and conduct their own due diligence. Lonestar Peptides makes no claim of therapeutic benefit.
